-
121por Nobari, Hadi, Praça, Gibson Moreira, da Glória Teles Bredt, Sarah, González, Pablo Prieto, Clemente, Filipe Manuel, Carlos-Vivas, Jorge, Ardigò, Luca Paolo“…Accelerometer-based variables were collected during training and match contexts and were used to generate indicators of weekly acute and chronic workload, training monotony, training strain and metabolic power. A one-way ANOVA compared all dependent variables between groups, and effect sizes for pairwise comparisons were calculated. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
122“…BACKGROUND: The ability to generate high levels of power is one of the key factors determining success in many sport disciplines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
123“…The degree distribution of both metabolic networks follows a power-law one, hence displaying a scale-free property. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
124“…Renewable energy sources have been placed as the key to facilitating to provide source of electricity generation. Solar power is one of the most preferable one among renewable energy sources due to the easy to generate in suitable environment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
125“…It included quality of life, power over one’s own life and experience of discrimination. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
126por Söderbäck, Kristina, Holter, Herborg, Salim, Sanura Abdulla, Elden, Helen, Bogren, Malin“…Perceived risks of modern contraceptive methods are described in the subcategories: fear of being harmed, and fear of irregular bleeding. Limited power in one’s own decision about contraceptive use consist of the subcategories: the need to involve the husband, and opposition and lack of interest from the husband. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
127por Bennett, Paul N, Parsons, Trisha, Ben-Moshe, Ros, Neal, Merv, Weinberg, Melissa K, Gilbert, Karen, Ockerby, Cherene, Rawson, Helen, Herbu, Corinne, Hutchinson, Alison M“…Data were analysed using IBM SPSS Statistics v22, including descriptive and inferential statistics, and sample size estimates were calculated using G*Power. RESULTS: One participant withdrew from the study for medical reasons that were unrelated to the study during the first week (94 % retention rate). …”
Publicado 2015
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
128por Brunello, Antonella, Fontana, Andrea, Zafferri, Valeria, Panza, Francesco, Fiduccia, Pasquale, Basso, Umberto, Copetti, Massimiliano, Lonardi, Sara, Roma, Anna, Falci, Cristina, Monfardini, Silvio, Cella, Alberto, Pilotto, Alberto, Zagonel, Vittorina“…The discriminatory power of one-year mortality prediction of the Onco-MPI was very good (survival C-index 0.87, 95 % CI 0.84–0.90) with an excellent calibration (HL p value 0.854). …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
129por Miroliaei, Mehran, Aminjafari, Akram, Ślusarczyk, Sylwester, Nawrot-Hadzik, Izabela, Rahimmalek, Mehdi, Matkowski, Adam“…The free radical scavenging activity was higher than Trolox and metal reducing power was one-third to half that of ascorbic acid. The activity of elastase and collagenase was inhibited by 54.75% ± 6.87% and 60.03% ± 7.22%, respectively. …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
130por Goéré, Diane, Pignon, Jean-Pierre, Gelli, Maximiliano, Elias, Dominique, Benhaim, Léonor, Deschamps, Frédéric, Caramella, Caroline, Boige, Valérie, Ducreux, Michel, de Baere, Thierry, Malka, David“…The first step is a non-comparative randomized phase II trial (power, 95%; one-sided alpha risk, 10%). Patients will be randomly assigned in a 1:1 ratio to adjuvant systemic FOLFOX (control arm) or adjuvant HAI oxaliplatin plus systemic LV5FU2 (experimental arm). …”
Publicado 2018
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
131por Nam, Denis, Lawrie, Charles M., Salih, Rondek, Nahhas, Cindy R., Barrack, Robert L., Nunley, Ryan M.“…Power analysis indicated that 130 patients were necessary to demonstrate a 5-point difference in the Oxford Knee Score at 90% power. RESULTS: One hundred and forty-seven patients were enrolled, and 141 (96%) of them were analyzed at an average of 2 years postoperatively. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
132por Derstine, Brian A., Holcombe, Sven A., Ross, Brian E., Wang, Nicholas C., Su, Grace L., Wang, Stewart C.“…Sex-specific allometric analysis showed that height to the power of one was the optimal integer coefficient for height adjusted SMA in both males and females. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
133por Osmancik, Pavel, Havránek, Štěpán, Bulková, Veronika, Chovančík, Jan, Roubíček, Tomáš, Heřman, Dalibor, Čarná, Zuzana, Tuka, Vladimír, Matoulek, Martin, Fiala, Martin, Jiravský, Otakar, Stregl-Hruskova, Sylvie, Latiňák, Adam, Kotryová, Jiřina, Jarkovský, Jiří“…An AF freedom of 65% in the RFM+AAD and of 60% in the CA is expected; therefore, 202 patients will be enrolled to achieve the non-inferiority with 80% power, 5% one-sided alpha and a non-inferiority margin of 12%. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
134por Crouse, Stephen F., Lytle, Jason R., Boutros, Sean, Benton, William, Moreno, Michael, McCulloch, Patrick C., Lambert, Brad S.“…At timepoint 2 72 h later, subjects completed a ventilatory-threshold-endurance-ride [VTER((s))] timed to exhaustion at [Formula: see text] O(2) @VT power ((W)). One week later at timepoints 3 and 4 (time-of-day controlled), subjects repeated testing protocols under the alternate mouthpiece condition. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
135por Beckermann, Kathryn, Haake, Scott, Reddy, Anupama, Shyr, Yu, Kimryn Rathmell, W, Pal, Sumanta, Ornstein, Moshe, Barata, Pedro, Zhang, Tian, Rini, Brian“…This trial adopts Simon’s MiniMax two-stage design (power: 80%, one-sided alpha: 0.1). For the nivolumab/cabozantinib arm, stage I will enroll 12 eligible patients. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
136por Stein, Mark N., Chen, Yu-Hui, Carducci, Michael A., Hudes, Gary R., Lerma, Pauline M., Tan, Winston W., Dalune, Robert, Rowland, Kendrith M., Kuzel, Timothy M., DiPaola, Robert S.“…The trial was powered to detect a 50% PSA reduction using Consensus Criteria in at least 40% versus 20% (90% power, one-sided α=0.10) for the CN stratum and 25% versus. 10% (power 87%, one-sided α=0.10) for the Tax and TCx strata. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
137por Lewis, M., Bromley, K., Sutton, C. J., McCray, G., Myers, H. L., Lancaster, G. A.“…RESULTS: For example, in relation to treatment fidelity, if we assume the upper boundary of the RED zone is 50% and the lower boundary of the GREEN zone is 75% (designating unacceptable and acceptable treatment fidelity, respectively), the sample size required for analysis given 90% power and one-sided 5% alpha would be around n = 34 (intervention group alone). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
138por 't Hart, Judith W H, Noordman, Bo J, Biter, Laser U, Leeuwenburgh, Ivonne, Dunkelgrun, Martin, Apers, Jan A“…A total of 88 patients with morbid obesity and GORD will be randomised to evaluate non-inferiority of Nissen-Sleeve versus LRYGB (non-inferiority margin 15%, power 80%, one-sided α 0.025, 9% drop out). Patients with morbid obesity aged 18 years and older with GORD according to the Montreal definition will be included after obtaining informed consent. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
139por Mukherjee, Somnath, Hurt, Christopher N, Gwynne, Sarah, Bateman, Andrew, Gollins, Simon, Radhakrishna, Ganesh, Hawkins, Maria, Canham, Jo, Lewis, Wyn, Grabsch, Heike I, Sharma, Ricky A, Wade, Wendy, Maggs, Rhydian, Tranter, Bethan, Roberts, Ashley, Sebag-Montefiore, David, Maughan, Timothy, Griffiths, Gareth, Crosby, Tom“…Secondary endpoints include: recruitment rate, toxicity, 30-day surgical morbidity/mortality, resection margin positivity rate and overall survival (median, 3- and 5-yr OS. 76 patients (38/arm) gives 90% power and one-sided type 1 error of 10% if patients on one novel treatment have a response rate of 35% while the second treatment has a response rate of 15%. …”
Publicado 2015
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
140por Modesto, Anouchka, Tougeron, David, Tremolières, Pierre, Ronchin, Philippe, Jouve, Ariane Darut, Leignel, Delphine Argo, Vendrely, Véronique, Riou, Olivier, Martin-Babau, Jérôme, Le Sourd, Samuel, Mirabel, Xavier, Leroy, Thomas, Huguet, Florence, Montaigne, Lucile, Baumgaertner, Isabelle, Deslandres, Marion, Moyal, Elizabeth, Seva, Catherine, Selves, Janick, Otal, Philippe, Pezzella, Veronica, Guimbaud, Rosine, Filleron, Thomas, Quéro, Laurent“…The primary endpoint is to increase progression-free survival at 12 months from 50 to 68% (HR = 0.55) (power 90%; one-sided alpha-risk, 10%). Progression will be defined with central external review of imaging. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto